Zensita M 50mg/1000mg Tablet is a combination oral antidiabetic medication containing Sitagliptin 50mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by increasing levels of active glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby improving glycemic control through increased insulin release and decreased glucagon secretion in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by enhancing peripheral glucose uptake and utilization. The fixed-dose combination offers complementary mechanisms of action, facilitating effective glycemic control in patients inadequately controlled on monotherapy or lifestyle interventions alone. Zensita M is administered orally, typically once or twice daily with meals to minimize gastrointestinal side effects. It is contraindicated in patients with renal impairment, metabolic acidosis, or known hypersensitivity to its components. Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which are generally transient. Regular monitoring of renal function and glycemic parameters is recommended during therapy. Zensita M should be used as part of a comprehensive diabetes management plan including diet and exercise.